PIK3CA mutation was associated with a lower risk of local relapse in this population of BCs. This is consistent with recent studies suggesting PIK3CA to be part of biological pathways impacting the radiosensitivity.

treatment after TKI-resistance while only emerging malignant effusion. And lung cancer related symptoms were caused mainly by malignant effusions. Patients were administrated by single bevacizumab 100mg intrapleural or intrapericardial injection after the drainage of effusions. Lung cancer symptom scale (LCSS), efficacy and safety were evaluated before and after the treatment. Result: Twenty patients with lung adenocarcinoma and two patients with lung squamous cell carcinoma were included in the study from January 2014 through March 2019. LCSS after the treatment (score 494±78, mean±SD) were significantly improved compared with that before the treatment (score 377±77, mean±SD) (paired differences: score 117±64, mean±SD, 95% CI: score 89-145, P<0.001). Malignant effusions decreased obviously three weeks after the treatment compared with those before the treatment (P<0.001). The median duration of response was 91 days (127±40 days, mean±SD) in the 14 patients receiving intrapleural injection, and 111 days (91±11days, mean±SD) in the 8 patients with intrapericardial injection. There was no significant difference in the remission time of local injection between malignant pleural and pericardial effusions (P¼0.987). Moreover, no severe side effects emerged, only one patient had mildly dizziness. Conclusion: Single bevacizumab intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, while rapidly improving the malignant effusion-related symptoms in NSCLC patients. Certainly furthermore clinical trials were needed to confirm the results.